Dupixent® (dupilumab) – New indication
April 18, 2025 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.
Top